Pharmaceutical Care for One Patient with Early Stage Breast Cancer Secondary Osteoporosis Treated with Letrozole
- VernacularTitle:1例应用来曲唑治疗的早期乳腺癌继发骨质疏松症患者的药学监护
- Author:
Yuanyuan LI
1
;
Chengliang ZHANG
;
Ling GUI
;
Aiping DENG
Author Information
1. 华中科技大学同济医学院附属武汉中心医院药学部 武汉430014
- Keywords:
Breast cancer;
Osteoporosis;
Clinical pharmacist;
Pharmaceutical care
- From:
China Pharmacist
2017;20(12):2201-2203
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the pharmaceutical care approaches for the patients with early breast cancer secondary osteoporo-sis treated with letrozole. Methods:A patient with early breast cancer treated with letrozole in long-term faced the high risk of second-ary osteoporosis and led to fracture. How to reduce the risk of fractures by using drugs was the breakthrough point of clinical pharma-cists, and then, individualized pharmaceutical care was performed. Results: The patient was assessed at high risk of fractures in 10 years, and clinical pharmacists assisted doctors to optimize drug therapy, and carried out long-term follow-up education to the patient. The waist pain of the patient disappeared in six months. Conclusion: For early breast cancer patients treated with letrozole, clinical pharmacists should consider the diet and living habits of the patients, assess the fracture risk in 10 years, adjust individual dose of cal-cium and vitamin D3 , choose appropriate bone absorption inhibitors and endocrine treatment, and perform follow-up for the long-term treatment compliance of the patients.
